Multicenter cohort study shows improved survival with DOACs in LVAD patients, suggesting a viable alternative to warfarin.
In this multicenter cohort, DOACs were associated with improved long-term survival and comparable safety outcomes relative to warfarin in LVAD patients. These findings suggest DOACs may be a viable alternative, but larger prospective studies are warranted.
No takes yet. Share an insight, caveat, or question.
Mhanna et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: